Agents in development for anxiety disorders: Current status and future potential

CNS Drugs

Volumn 13, Issue 6, 2000, Pages 421-431

  Hood, Sean D ^a   Argyropoulos, Spilios V ^a   Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 7 CHLORO 5 [(3,5 DIMETHYLPIPERAZINO)CARBONYL]IMIDAZO[1,5 A]QUINOLINE 3 CARBOXYLIC ACID TERT BUTYL ESTER; ABECARNIL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANXIOLYTIC AGENT; APREPITANT; DERAMCICLANE FUMARATE; DOPAMINE RECEPTOR AFFECTING AGENT; FG 7516; GABAPENTIN; GEPIRONE; GIRISOPAM; INOSITOL; L 75030; LP 456; LY 191617; ME 3127; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE RECEPTOR; NEUROSTEROID; NGD 912; NS 2710; ONDANSETRON; PAGOCLONE; PAZINACLONE; PRASTERONE; PREGABALIN; RECEPTOR BLOCKING AGENT; SEROTONIN RECEPTOR AFFECTING AGENT; TIAGABINE; U 101017; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZATOSETRON; ZATOSETRON MALEATE;

ANXIETY NEUROSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GABAERGIC TRANSMISSION; HUMAN; NONHUMAN; NORADRENERGIC SYSTEM; OBSESSION; PANIC; PEPTIDERGIC NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0034046124     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013060-00004     Document Type: Review

References (104)

1. 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
2. 2. Regier DA, Boyd JH, Rae DS, et al. One-month prevalence of mental disorders in the US: based on five epidemiologic catchment area (ECA) sites. Arch Gen Psychiatry 1988; 45: 977-86
3. 3. Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 1998; 59 Suppl. 8: 11-6
4. 4. Candilis PJ, McLean RY, Otto MW, et al. Quality of life in patients with panic disorder. J Nerv Ment Dis 1999 Jul; 187 (7): 429-34
5. 5. Ballenger JC. Selective serotonin reuptake inhibitors (SSRIs) in panic disorder. Nutt DJ, Ballenger JC, Lepine J-P, editors. Panic disorder. Clinical diagnosis, management and mechanisms. London: Martin Dunitz, 1999: 159-78
6. 6. Graeff FG, Silveira MC, Nogueira RL, et al. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 1993; 58 (1-2): 123-31
7. 7. Graeff FG, Viana MB, Mora PO. Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 1997; 21 (6): 791-9
8. 8. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998; 44 (12): 1264-76
9. 9. Reilly JG, McTavish SFB, Young AH. Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. J Psychopharmacology 1997; 11: 381-92
10. 10. Ȧberg-Wisted A, Hasselmark L, Stain-Malmgren R, et al. Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 1998; 97: 374-80
11. 11. Bremner JD, Innis RB, Salomon RM, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997; 54, 364-74
12. 12. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 45, 2323-32
13. 13. Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge for patients with major depression: relevance to antidepessant action and the neurobiology of depression. Psychopharmacol Bull 1991; 29: 389-96
14. 14. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role in the mechanism of antidepressant action. Biol Psychiatry 1999; 46: 212-20
15. 15. Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51, 309-17
16. 16. Smeraldi E, Diaferia G, Erzegovesi S, et al. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 1996; 40: 398-402
17. 17. Rasmusson AM, Anderson GM, Lynch KA, et al. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry 1997; 41, 117-21
18. 18. Nutt D, Forshall S, Bell C, et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 1999; 9 Suppl. 3: S81-6
19. 19. Pecknold JC. Serotonin abnormalities in panic disorder. In: Ballenger JC, editor. Neurobiology of panic disorder. New York (NY): Wiley-Liss, 1990: 121-42
20. 20. File SE, Hyde JRG. The effects of p-chlorophenylalanine and ethanolamine-O-sulphate in an animal test of anxiety. J Pharmacol 1977; 29: 735-8
21. 21. Graeff NG, Filho NGS. Behavioural inhibition induced by electrical stimulation of the median raphe nucleus of the rat. Physiol Behav 1978; 21: 477-84
22. 22. Charney DS, Heninger GR. Abnormal regulation of noradrenergic function in panic disorders: effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43 (11): 1042-54
23. 23. Kahn RS, Westenberg HG, Verhoeven WM, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987; 2 (1): 33-45
24. 24. Charney DS, Woods SW, Goodman WK, et al. Serotonin function in anxiety: II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology Berl 1987; 92 (1): 14-24
25. 25. Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic function in obsessive-compulsive disorder: Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992 Jan; 49 (1): 21-8
26. 26. Eriksson E, Engberg G, Bing O, et al. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 1999; 20 (3): 287-96
27. 27. Germine M, Goddard AW, Sholomskas DE, et al. Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 1994; 54 (2): 115-33
28. 28. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173 Suppl. 35: 64-70
29. 29. Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsive disorder. Depress Anxiety 1998; 8 Suppl. 1: 105-13
30. 30. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998 Sep 1: 44 (5): 313-23
31. 31. Rickels K, Schweizer E, De Martinis M, et al. Gepirone and diazepam in generalised anxiety disorders: a placebo-controlled trial. J Clin Psychopharmacol 1997; 17: 272-7
32. 32. Pecknold JC, Luthe L, Scott Fleury MH, et al. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 1993; 13 (2): 145-9
33. 33. Berenyi E, Blasko G, Fekete M, et al. EGYT-3886. Drugs Future 1990 Dec; 15: 1174-5
34. 34. Detari L, Szentgyorgyi V, Hajnik T, et al. Differential EEG effects of the anxiolytic drugs, deramciclane (EGIS-3886), ritanserin and chlordiazepoxide in rats. Psychopharmacology Berl 1999 Mar; 142 (3): 318-26
35. 35. Freeman AM, Westphal JR, Norris GT, et al. The efficacy of ondansetron in the treatment of generalised anxiety disorder. Depress Anxiety 1997; 5: 140-1
36. 36. Depot M, Merani S, Bradwejn J, et al. Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. J Psychiatry Neurosci 1998; 23 (5): 298-304
37. 37. Schneier FR, Garfinkel R, Kennedy B, et al. Ondansetron in the treatment of panic disorder. Anxiety 1996; 2 (4): 199-202
38. 3 antagonist, ondansetron in social phobia [poster]. Presented at the 33rd Annual Meeting of the American College of Neuropsychopharmacology; 1994 Dec 12-16; San Juan, Puerto Rico
39. 39. Smith WT, Londborg PD, Blomgren SL, et al. Pilot study of zotosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol 1999 Apr; 19: 125-31
40. 40. Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressants in the treatment of PTSD. Depress Anxiety 1997; 5: 137-9
41. 41. van Vliet IM, Westenberg HGM, den Boer JA. Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology 1996 Sep; 127: 174-80
42. 42. Deren-Wesolek A, Tatarcznska E, Chojnacka-Wojcik E. The novel buspirone analogue, 8-[4-[2-(1,2,3,4-tetrahydroisoquinolinyl) [butyl] -8-azaspiro [4.5] decane-7,9-dione, with anxiolytic-like and antidepressant-like effects in rats. J Psychopharmacol 1998; 12 (4): 380-4
43. 43. Hanes KR. Serotonin, psilocybin, and body dysmorphic disorder: a case report. J Clin Psychopharmacol 1996; 16: 188-9
44. 44. Baumgarten HG, Grozdanovic Z. Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998; 35: 13-20
45. 45. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 1994; 55 Suppl. 3: 24-31
46. 46. Koran L, Ringold A, Elliott M. Olanzapine added to fluoxetinc in unresponsive obsessive-compulsive disorder [abstract 3.020]. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S305
47. 47. O'Hanlon JF, Robbe HW, Verneeren A, et al. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens. J Clin Psychopharmacol 1998 Jun; 18 (3): 221-21
48. 48. American Home Products Corporation. American Home Products announces Effexor (R) XR receives FDA approval for the treatment of generalized anxiety disorder. Media Release. 1999 Mar 12; 3 pages
49. 49. Wyeth-Ayerst Laboratories. New studies demonstrate long-term effectiveness of Effexor (R) XR in treating symptoms of generalised anxiety disorder. Media Release. 1999 Mar 26; 2 pages
50. 50. Hackett D, Haudiquet V, Salinas E. A dose-response, 6 month evaluation of venlafaxine extended-release in outpatients with generalized anxiety disorder [abstract]. The Summer Meeting of the British Association for Psychopharmacology; 1999 Jul 25; J Psychopharmacol 1999; 13 (3): A44
51. 51. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995; 31 (4): 767-71
52. 52. Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999 Jul; 14 (4): 239-45
53. 53. Koran L, Quirk T, Lorberbaum J. Mirtazepine treatment of obsessive-compulsive disorder [abstract P.3.022]. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S305-S306
54. 54. Longhurst JG, Carpenter LL, Epperson CN, et al. Effects of catecholamine depletion with AMPT (alpha-methyl-paratyrosine) in obsessive-compulsive disorder. Biol Psychiatry 1999 Aug 15; 46 (4): 573-6
55. 55. Braestrup C, Squires RF. Brain specific benzodiazepine receptors. Br J Psychiatry 1978 Sep; 133: 249-60
56. 56. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999 Apr; 29 (2-3): 196-217
57. A receptor subtypes. Nature 1999 Oct 21; 401: 796-800
58. 58. Pincock C, Jensen NO, Oliver S, et al. Cognitive effects of multiple doses of ME3127, a novel anxiolytic, in volunteers [abstract P71]. J Psychopharmacol 1999; 13 (3 Suppl. A): A27
59. 59. Jones S, Jensen NO, Oliver S, et al. Cognitive effects of single-doses of ME3127, a novel anxiolytic, in volunteers [abstract P70]. J Psychopharmacol 1999; 13 (3 Suppl. A): A27
60. 60. Linden M, Hadler D, Hofmann S. Randomised, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalised anxiety. Hum Psychopharmacol Clin Exper 1997 Sep; 12: 445-52
61. 61. Evans SM, Fukuda N, Levin FR, et al. Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 1995 Mar; 6: 176-86
62. 62. Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN-2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology 1995 Oct; 121 (4): 442-50
63. 63. Interneuron Pharmaceuticals Inc. Interneuron's pagoclone significantly reduces panic attacks in phase 2/3 clinical trial. Media Release. 1998 Aug 17; 2 pages
64. 64. Interneuron Pharmaceuticals Inc. Interneuron's announces positive phase 2 data on pagoclone in panic disorders. Media Release. 1997 Nov 20; 2 page.
65. 65. Tang AH, Franklin SR, Carter DB, et al. Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor. Psychopharmacology 1997 Jun; 131: 255-63
66. 66. Mumford GK, Rush CR, Griffiths RR. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exper Ther 1995 Feb; 272: 570-80
67. 67. Aufdembrinke B. Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. Br J Psychiatry 1998 Jul; 173 Suppl. 34: 63
68. 68. Argyropoulos S, Nutt D. Peptide receptors as targets for anxiolytic drugs. In: Briley M, Nutt D, editors. Milestones in drug therapy: anxiolytics. Basel: Birkhauser Verlag, 2000. In press
69. 69. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors [see comments]. Science 1998 Sep 11; 281 (5383): 1640-5
70. 70. Adams JB, Pyke RE, Costa J, et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995 Dec; 15 (6): 428-34
71. 71. Goddard AW, Woods SW, Money R, et al. Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 1999 Mar 22; 85 (3): 225-40
72. 72. van Megen HJ, Westenberg HG, den Boer JA, et al. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacol Berl 1997 Feb; 129 (3): 243-8
73. 73. Hasenohrl RU, Jentjens O, De Souza-Silva MA, et al. Anxiolytic-like action of neurokinin substance Padministered systemically or into the nucleus basalis magnocellularis region. Eur J Pharmacol 1998 Aug 7; 354 (2-3): 123-33
74. 74. Nutt D. Substance-P antagonists: a new treatment for depression? Lancet 1998 Nov 21; 352: 1644-5
75. 75. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 1999 Apr; 82 (1): 1-61
76. 76. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings [sec comments]. Arch Gen Psychiatry 1989 Jun; 46 (6): 511-7
77. 77. van Megen HJ, Westenberg HG, den Boer JA, et al. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 1996; 6 (3): 187-94
78. 78. Brawman Mintzer O, Lydiard RB, Bradwejn J, et al. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 1997; 154 (5): 700-2
79. 79. De Leeuw AS, den Boer JA, Slaap BR, et al. Pentagastrin has panic-inducing properties in obsessive compulsive disorder. Psychopharmacol Berl 1996; 126 (4): 339-44
80. 80. van Vliet IM, Westenberg HG, Slaap BR, et al. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol Psychiatry 1997, 42 (1): 76-8
81. 81. van Megen HJ, Westenberg HG, den Boer JA, et al. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacol Berl 1997; 129 (4): 357-64
82. 82. van Megen HJ, Westenberg HG, den Boer JA, et al. Cholecystokinin in anxiety. Eur Neuropsychopharmacol 1996; 6 (4): 263-80
83. 83. Becker C, Hamon M, Benoliel JJ. Prevention by 5-HT1A receptor agonists of restraint stress-and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Neuropharmacology 1999 Apr; 38 (4): 525-32
84. 84. Gewirtz JC, Davis M. Beyond attention: the role of amygdala NMDA receptors in fear conditioning [commentary]. Behav Brain Sci 1997 Dec; 20 (4): 618
85. 85. Lensi P, Cassano GB, Correddu G, et al. Obsessive-compulsive disorder: familial-developmental history, symptomatology, comorbidity and course with special reference to gender-related differences. Br J Psychiatry 1996; 169 (1): 101-7
86. 86. Kunovac JL, Stahl SM. Future directions in anxiolytic pharmacotherapy. Psychiatr Clin North Am 1995 Dec; 18 (4): 895-909
87. 87. Liebsch G, Landgraf R, Engelmann M, et al. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 1999 Mar; 33 (2): 153-63
88. 88. Rasmusson AM, Southwick SM, Hauger RL, et al. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Neuropsychopharmacology 1998; 19 (1): 95-8
89. 89. Grundemar L, Håkanson R. Neuropeptide Y effector systems: perspectives for drug development. Trends Pharmacol Sci 1994 May; 15 (5): 153-9
90. 90. Stein MB, Hauger RL, Dhalla KS, et al. Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia. Psychiatry Res 1996; 59 (3): 183-8
91. 91. Boulenger JP, Jerabek I, Jolicoeur FB, et al. Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am J Psychiatry 1996; 53 (1): 114-6
92. 92. Adamec RE, Burton P, Shallow T, et al. Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle: effective hemisphere depends on the behavior. Physiol Behav 1999 Jan 1; 65 (4-5): 739-51
93. 93. Cratty MS, Birkle DL. N-methyl-D-aspartate (NMDA)-mediated corticotropin-releasing factor (CRF) release in cultured rat amygdala neurons. Peptides 1999; 20 (1): 93-100
94. 94. Adamec RE, Burton P, Shallow T, et al. NMDA receptors mediate lasting increases in anxiety-like behavior produced by the stress of predator exposure: implications for anxiety associated with posttraumatic stress disorder. Physiol Behav 1999 Jan 1; 65 (4-5): 723-37
95. 95. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999 Jun; 38 (6): 735-67
96. 96. Gasior M, Carter RB, Witkin JM. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol Sci 1999 Mar; 20 (3): 107-12
97. 97. Rupprecht R, Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids 1999 Jan; 64 (1-2): 83-91
98. 98. Frye CA, Lacey EH. The neurosteroids DHEA and DHEAS may influence cognitive performance by altering affective state. Physiol Behav 1999 Mar; 66 (1): 85-92
99. 99. Pande AC, Davidson JRT, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19 (4): 341-8
100. 100. Benjamin J, Levine J, Fux M, et al. Inositol treatment for panic disorder: a double-blind placebo-controlled crossover trial. Am J Psychiatry 1995; 152: 1084-6
101. 101. Fux M, Levin FR, Aviv A, et al. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996; 153: 1219-21
102. 102. de Paris F, Busnello JV, Vianna MRM, et al. Gabapentin presents anxiolytic but not amnestic effects in rats [abstract P105]. J Psychopharmacol 1999; 13 (3 Suppl. A): A36
103. 103. Kaplan Z, Amir M, Swartz M, et al. Inositol treatment of posttraumatic stress disorder. Anxiety 1996; 2: 51-2
104. 104. Walkup J, Reeve E, Yaruyura-Tobias J, et al. Fluvoxamine in childhood OCD: long-term treatment [abstract P.3.025]. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S307